SANM

193.2304.13%

Pre-market hot trades in US stocks: Wetour Robotics pre-market down 7.56%; Sanmina pre-market down 7.15%

Price Alert

Jul 28, 2026 at 04:43 AM

I'm LongbridgeAI, I can summarize articles.

Wetour Robotics pre-market down 7.56%; Sanmina pre-market down 7.15%; C3is pre-market up 146.58%; Inlif pre-market up 43.90%; Gossamer Bio pre-market up 39.37%

Pre-market Hot Trades in US Stocks

Wetour Robotics is down 7.56% in pre-market trading. There have been no significant news recently; trading is active with clear capital flows. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. no_news

Sanmina is down 7.15% in pre-market trading. Based on recent key news:

On July 27, Sanmina announced its third-quarter financial report, with revenue increasing by 69.7% year-on-year, but manufacturing efficiency issues have put pressure on some profit margins. Despite strong revenue growth, concerns over manufacturing efficiency have led to a decline in stock price.
On July 27, Sanmina established a strategic partnership with AMD to accelerate AI system deployment. Although this move is beneficial for future growth, it has not alleviated market concerns about current financial performance in the short term, putting pressure on the stock price.
On July 27, analysts maintained a hold rating on Sanmina, believing that five other stocks have more investment value. The analysts' cautious attitude further affected market confidence, leading to a decline in stock price. The AI industry is growing rapidly, and market competition is fierce.

Top Gainers in Pre-market US Stocks

C3is is up 146.58% in pre-market trading. Based on recent key news:

On July 27, C3is announced a public offering at a price of $0.52 per unit, with expected total proceeds of approximately $6 million. This move has enhanced market confidence in the company's liquidity, driving the stock price up. Source: Reuters
On July 25, C3is executed a 1-for-7 reverse stock split and reported a 358% surge in adjusted net income for the first quarter to $5.5 million. This financial performance has raised investors' expectations for the company's profitability. Source: Reuters
On July 27, C3is registered a statement with the SEC to enter the US capital market, financing its operations and growth plans through equity and warrant structures. This move has expanded the company's influence in the capital market. Source: Reuters Industry investment peaks, significant capital flows

Inlif is up 43.90% in pre-market trading. Based on recent key news:

On July 24, the Securities and Exchange Commission issued an announcement regarding important information disclosure involving Inlif. This announcement may have a positive impact on market sentiment, driving the stock price up.
On July 28, Brenmiller Energy announced that the European Investment Bank executed a waiver for deferred loan payments. This news may have a ripple effect on related industries, indirectly affecting Inlif's stock price.
On July 28, SK Telecom and United Microelectronics saw their stock prices drop by 9.8% and 7.2%, respectively, and the overall market sentiment towards tech stocks may affect Inlif's trading activity. Tech stocks have been volatile recently, and market sentiment needs to be monitored Gossamer Bio pre-market rose 39.37%. Based on recent key news:
On July 28, Gossamer Bio plans to submit a New Drug Application for seralutinib in September 2026 after a Pre-NDA meeting with the FDA. This move has boosted market confidence in the company's future development, driving up the stock price. Source: Benzinga
On July 27, the company announced it had regained global development and commercial rights for seralutinib and plans to conduct a reverse stock split to optimize its capital structure. This series of strategic adjustments has been viewed by the market as a positive signal, further boosting the stock price. Source: Business Wire
On July 27, Gossamer Bio shareholders approved the convertible note exchange and reverse stock split proposal aimed at supporting compliance with Nasdaq's minimum bid requirements. This move is seen as an improvement in the company's financial health, attracting investor attention. Source: Public Technologies The biopharmaceutical industry has recently seen favorable policies, with significant capital inflow

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Pre-market Hot Trades in US Stocks

Sanmina is down 7.15% in pre-market trading. Based on recent key news:

On July 27, Sanmina announced its third-quarter financial report, with revenue increasing by 69.7% year-on-year, but manufacturing efficiency issues have put pressure on some profit margins. Despite strong revenue growth, concerns over manufacturing efficiency have led to a decline in stock price.
On July 27, Sanmina established a strategic partnership with AMD to accelerate AI system deployment. Although this move is beneficial for future growth, it has not alleviated market concerns about current financial performance in the short term, putting pressure on the stock price.
On July 27, analysts maintained a hold rating on Sanmina, believing that five other stocks have more investment value. The analysts' cautious attitude further affected market confidence, leading to a decline in stock price. The AI industry is growing rapidly, and market competition is fierce.

Top Gainers in Pre-market US Stocks

C3is is up 146.58% in pre-market trading. Based on recent key news:

On July 27, C3is announced a public offering at a price of $0.52 per unit, with expected total proceeds of approximately $6 million. This move has enhanced market confidence in the company's liquidity, driving the stock price up. Source: Reuters
On July 25, C3is executed a 1-for-7 reverse stock split and reported a 358% surge in adjusted net income for the first quarter to $5.5 million. This financial performance has raised investors' expectations for the company's profitability. Source: Reuters
On July 27, C3is registered a statement with the SEC to enter the US capital market, financing its operations and growth plans through equity and warrant structures. This move has expanded the company's influence in the capital market. Source: Reuters Industry investment peaks, significant capital flows

Inlif is up 43.90% in pre-market trading. Based on recent key news:

On July 24, the Securities and Exchange Commission issued an announcement regarding important information disclosure involving Inlif. This announcement may have a positive impact on market sentiment, driving the stock price up.
On July 28, Brenmiller Energy announced that the European Investment Bank executed a waiver for deferred loan payments. This news may have a ripple effect on related industries, indirectly affecting Inlif's stock price.
On July 28, SK Telecom and United Microelectronics saw their stock prices drop by 9.8% and 7.2%, respectively, and the overall market sentiment towards tech stocks may affect Inlif's trading activity. Tech stocks have been volatile recently, and market sentiment needs to be monitored Gossamer Bio pre-market rose 39.37%. Based on recent key news:
On July 28, Gossamer Bio plans to submit a New Drug Application for seralutinib in September 2026 after a Pre-NDA meeting with the FDA. This move has boosted market confidence in the company's future development, driving up the stock price. Source: Benzinga
On July 27, the company announced it had regained global development and commercial rights for seralutinib and plans to conduct a reverse stock split to optimize its capital structure. This series of strategic adjustments has been viewed by the market as a positive signal, further boosting the stock price. Source: Business Wire
On July 27, Gossamer Bio shareholders approved the convertible note exchange and reverse stock split proposal aimed at supporting compliance with Nasdaq's minimum bid requirements. This move is seen as an improvement in the company's financial health, attracting investor attention. Source: Public Technologies The biopharmaceutical industry has recently seen favorable policies, with significant capital inflow